Jefferies Downgrades Moderna to Hold, Lowers Price Target to $65
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Michael Yee has downgraded Moderna from Buy to Hold and reduced the price target from $120 to $65.
September 13, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Jefferies has downgraded Moderna from Buy to Hold and significantly lowered the price target from $120 to $65, indicating a less optimistic outlook on the stock.
The downgrade from Buy to Hold and the significant reduction in the price target from $120 to $65 by Jefferies suggests a negative short-term outlook for Moderna's stock. This could lead to a decrease in investor confidence and a potential drop in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100